avelumab
pfizer,merck
['avelumab', 'cml']
first data on pd-l1 inhibition in the avenue trial presented by . orr 44.7% after 4x avelumab, 2x tumor flare, g3/4 aes in 20% of pts. avelumab did not impair later delivery of rathl-like chemotherapy, 1-year pfs 100%. looking forward to fu and correlatives. #icml2023 
Physician Scientist @UKKoeln & @MPIAGE. Hemato-Oncology, Lymphoma, Immunotherapy. Views are mine & no advise, RT/like no endorsement. COI: https://t.co/lOCrBZDrQP